Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA9 | P38646 | 11/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.49 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.44 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21750715 | 0.89 | HSPA9 (1.00) | HSPA9EPHX2 | |
| SCHEMBL21750646 | 0.86 | HSPA9 (1.00) | HSPA9EPHX2 | |
| SCHEMBL21750742 | 0.83 | HSPA9 (1.00) | HSPA9 | |
| SCHEMBL21750784 | 0.79 | HSPA9 (1.00) | HSPA9EPHX2BAZ1AMTOR | |
| SCHEMBL21750763 | 0.75 | HSPA9 (1.00) | HSPA9 | |
| SCHEMBL21750765 | 0.73 | HSPA9 (1.00) | HSPA9 | |
| SCHEMBL28729179 | 0.70 | EPHX2 (1.00) | EPHX2BAZ1AMTOR | |
| SCHEMBL11003408 | 0.70 | EPHX2 (1.00) | EPHX2BAZ1AMTOR | |
| SCHEMBL22803976 | 0.68 | HSPA9 (0.58) | HSPA9EPHX2BAZ1AMTORKCNJ6 | |
| SCHEMBL21750699 | 0.67 | HSPA9 (0.50) | HSPA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947198-B2 | Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2021-03-16 | — | — | US | claimed |
| US-20200062711-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2020-02-27 | — | — | US | claimed |
| US-11993573-B2 | Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2024-05-28 | — | — | US | disclosed |
| US-20210163415-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2021-06-03 | — | — | US | disclosed |
| US-10947198-B2 | Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200062711-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163415-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | HCCS, CDYL, XPOT | HSPA9 2213/4885EPHX2 2750/4885BAZ1A 2521/4885 |
| US-10947198-B2 | Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents | HCCS, CDYL, XPOT | HSPA9 2213/4885EPHX2 2750/4885BAZ1A 2521/4885 |
| US-11993573-B2 | Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents | HCCS, CDYL, CDYL2 | HSPA9 3140/4885EPHX2 2450/4885BAZ1A 2625/4885 |
| US-20200062711-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | HCCS, CDYL, XPOT | HSPA9 2213/4885EPHX2 2750/4885BAZ1A 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.